Drug name - Ozurdex
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10702539 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(3 months from now) | |
| US8506987 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(3 months from now) | |
| US8034370 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(3 months from now) | |
| US8034366 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(3 months from now) | |
| US9192511 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(3 months from now) | |
| US10076526 | ALLERGAN | Ocular implant made by a double extrusion process |
Jan, 2023
(3 months from now) | |
| US6899717 | ALLERGAN | Methods and apparatus for delivery of ocular implants |
Nov, 2023
(1 year, 29 days from now) | |
Drugs and Companies using DEXAMETHASONE ingredient
Treatment: Treatment of diabetic macular edema; treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); treatment of non-infectious uveitis affecting the posterior segment of the eye; Treatment of macular edema; treatment of uveitis; Delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex
Dosage: IMPLANT;INTRAVITREAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 0.7MG | IMPLANT;INTRAVITREAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.